Weight-loss supplements and the FDA Part 4 In the last year alone, (pharmaceutical) companies in the U.S. abandoned two promising drugs -- rimonabant [known (commercially) as Acomplia] and taranabant -- after regulators raised concerns about their safety and questioned their (effectiveness) for long-term weight loss. Aside from a wide range of amphetamines, only two drugs on the market have been approved for (weight) loss by the FDA: Meridia, which increases a user's feeling of (fullness), and the over-the-counter fat-blocker orlistat, marketed as Alli. That dearth of FDA-approved (options) has been a bonanza for the dietary supplements industry, which is not required (by) law to provide proof of a product's safety or effectiveness before (putting) it on the market. Americans spent $1.67 billion in 2007 on dietary supplements (pitched) as appetite suppressants, fat burners, satiety aids and (meal) replacements to help with weight loss, according to the Nutrition Business Journal. Of the hundreds of weight-loss aids on the dietary supplements market, Hydroxycut had (established) itself among the most visible and (bestselling0. In 2008, the company sold 19 million units of its various (pills) and powders.
相关阅读:
医学英语口语课程
医学英语水平免费测试